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The efficacy of therapeutics is often diminished by their insolubility, instability, low
bioavailability, non-specificity and systemic toxicity. A considerable number of strategies
have been developed in order to obtain drug delivery systems for an effective therapy.
Attachment of drugs to suitable polymers significantly alters their properties and phar-
macokinetics. Polymer conjugation, largely investigated with both protein and low mo-
lecular mass drugs, represents a promising method to improve the physicochemical and
biopharmaceutical properties of drugs (1, 2). Polymer conjugation can endow derivatives
with increased water-solubility and chemical stability, improved pharmacokinetics and
distribution profile, reduced side effects, and sometimes properties targeted at the dis-
ease site either by active or passive mechanisms (3).
Styrene-maleic acid anhydride copolymer (SMA) belongs to a group of vinylic poly-
mers. It has no teratogenic, and no acute or chronic toxic effects (4, 5). It is currently in
clinical trials as an efficient, reversible male contraceptive (6, 7). SMA has also been used
for the preparation of chemically and diffusionally controlled polymeric prodrugs of py-
razolone and phenothiazine derivatives (8), barbituric acid and xantine derivatives (9),
dopamine (10), ampicillin (11) or acriflavine (12). There are also examples of attachment
of some antimicrobial agents such as 4-aminobenzoic acid, 4-hydroxybenzoic acid (9, 13)
and 4-aminophenol (14) to SMA. However, the most successful example is attachment of
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the protein drug neocarzinostatin to SMA via two amide bonds. Clinical results are ex-
tremely promising with a success rate of 70–90% of the treated tumour patients (1517).
Fenoprofen is a non-steroidal anti-inflammatory drug with analgesic activity (18). It
is indicated in musculoskeletal and joint disorders such as osteoarthritis, rheumatoid ar-
thritis and ankylosing spondylitis, as well as in management of mild to moderate pain,
fever and inflammation. Gemfibrozil is a lipid-lowering agent, derivative of fibric acid.
It is widely used in the treatment of dyslipidaemias and atherosclerosis, especially in li-
poprotein disorders characterized by elevation of very-low-density lipoproteins (VLDL)
and plasma triglycerides. Due to their relatively short plasma half-life, both drugs should
be given in repeated doses to maintain a therapeutic effect. To overcome these problems,
a number of prodrugs and structural analogues of fenoprofen and gemfibrozil have been
prepared and evaluated. In our previous papers, binding of fenoprofen and gemfibrozil
to biodegradable polyaspartamide-type polymers by ester or amide bonds was reported
(1924). Hydrolysis studies showed that drugs could be released from the macromole-
cular prodrugs after chemical hydrolysis in a wide pH range.
In this paper, we report the reaction of fenoprofen and gemfibrozil amide deriva-
tives with styrene-maleic acid anhydride copolymer and characterization of the result-
ing polymer-drug conjugates.
EXPERIMENTAL
IR spectra were recorded on a FT-IR Paragon 500 spectrometer (Perkin-Elmer, UK)
and UV spectra on a Hewlett Packard 8452A diode array spectrophotometer (Hewlett
Packard, Germany). For thin layer chromatography, silica gel sheets Kieselgel 60 F254
(Merck, Germany) were used. Solvent systems were cyclohexane/ethyl acetate/metha-
nol (1:3:1), butanol/water/acetic acid (8:1:1) and cyclohexane/ethyl acetate (1:1). UV
light (254 nm) and iodine vapour were used for spot detection. Fenoprofen was pur-
chased from Eli Lilly Company (USA). Gemfibrozil was obtained from Lek (Slovenia).
The amines were distilled and dried prior to use. All solvents were of analytical grade
and dry.
N-1-benzotriazolecarboxylic acid chloride (1)
Compound 1 was prepared according to the previously published procedure (25).
Benzotriazolides of fenoprofen and gemfibrozil (2a,b)
Compounds 2a and 2b were prepared by reaction of N-1-benzotriazolecarboxylic acid
chloride (1) and fenoprofen or gemfibrozil, following the published procedures (19, 26).
2-Aminoethyl fenoprofenamide (3a) and 2-aminoethyl gemfibrozilamide (3b)
Compounds 3a and 3b were prepared according to the previously published proce-
dures (20, 21).
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Styrene-maleic acid anhydride copolymer (SMA, 4)
SMAwas prepared following the procedure described by Kova~-Filipovi} et al. (27).
(Styrene-maleic acid copolymer)-ethylenediamine-fenoprofen conjugate
(SMAC-EDA-Fen, 5a)
A solution containing 0.220 g (0.0011 mol calculated as a monomer unit) SMA (4),
0.310 g (0.0011 mol) 3a and 0.111 g (0.0011 mol) triethylamine (TEA) in 12 mL N,N-di-
methylformamide (DMF) was stirred at 50 C for 7 h. After cooling, the solution was
poured into 50 mL of hydrochloric acid (w = 1%). Resulting precipitate was filtered off
and washed with water until neutral IR (KBr): max 3318, 2932, 1724, 1653, 1582, 1534,
1490, 1244, 1208, 932, 761, 700 cm–1; nitrogen analysis (%) for monomer unit C29H30N2O5
(486.61): calcd. N 5.76, found: N 5.42; drug loading: 46.9%.
(Styrene-maleic acid copolymer)-ethylenediamine-gemfibrozil conjugate
(SMAC-EDA-Gem, 5b)
A solution containing 0.220 g (0.0011 mol calculated as a monomer unit) SMA (4),
0.320 g (0.0011 mol) 3b and 0.111 g (0.0011 mol) TEA in 7 mL DMF was stirred at 50 C
for 7 h. After cooling the solution was poured into 50 mL of hydrochloric acid (w = 1%).
Resulting precipitate was filtered off and washed with water until neutral IR (KBr):
max 3340, 2951, 1724, 1642, 1613, 1531, 1510, 1454, 1263, 1129, 1040, 702 cm–1; nitrogen
analysis (%) for monomer unit C29H38N2O5 (494.69): calcd. N 5.66, found: N 4.62; drug
loading: 41.3%.
(Styrene-2-hydroxyethyl maleamide)-(styrene-maleic acid)
copolymer-ethylenediamine-fenoprofen conjugate (SHM-EDA-Fen, 6a)
A solution composed of 0.202 g (0.001 mol calculated as a monomer unit) SMA (4),
0.093 g (0.00033 mol) 3a and 0.101 g (0.001 mol) TEA in 7 mL DMF was stirred at 50 C
for 5 h. To the reaction mixture, 1 mL (1.012 g, 0.017 mol) of ethanolamine was added,
and the reaction continued for an additional 5 h. After cooling, the solution was poured
into 50 mL of hydrochloric acid (w = 1%). Resulting precipitate was filtered off, tritu-
rated and washed with water until neutral IR (KBr): max 3412, 2937, 1734, 1654, 1541,
1456, 1243, 702 cm–1; UV: max 276 nm (A = 0.497;  = 240.4 g mL–1, methanol); drug
loading: 29.6%.
(Styrene-2-hydroxyethyl maleamide)-(styrene-maleic acid)
copolymer-ethylenediamine-gemfibrozil conjugate (SHM-EDA-Gem, 6b)
A solution made up of 0.202 g (0.001 mol calculated as a monomer unit) SMA (4),
0.096 g (0.00033 mol) 3b and 0.101 g (0.001 mol) TEA in 7 mL DMF was stirred at 50 C
for 3.5 h. To the reaction mixture, 1 mL (1.012 g, 0.017 mol) of ethanolamine was added
and the reaction continued for an additional 1 h. After cooling, the solution was poured
into 50 mL of hydrochloric acid (w = 1%). Resulting precipitate was filtered off, tritu-
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rated and washed with water until neutral IR (KBr): max 3422, 2948, 1730, 1649, 1537,
1454, 1261, 703 cm–1; UV: max 276 nm (A = 0.591;  = 392.0 g mL–1, H2O); drug loading:
17.0%.
RESULTS AND DISCUSSION
In the first step, fenoprofen and gemfibrozil reacted with N-1-benzotriazolecarbo-
xylic acid chloride (1), affording the corresponding benzotriazolides 2a and 2b, respec-
tively. The reactions were performed in dry toluene, with the reactants ratio 1:1, in the
presence of TEA as HCl acceptor. In the reaction with ethylenediamine, benzotriazolides
2 were transformed into 2-aminoethyl fenoprofenamide (3a) and 2-aminoethyl gemfi-
brozilamide (3b), drug derivatives with free amino groups (Scheme 1) (20, 21). In this re-
action, amine excess was essential in order to prevent the formation of bis-ethylenedia-
mides.
Compounds 3a,b proved to be useful in the synthesis of polymer-drug conjugates.
Free amino groups enabled their reaction with anhydride rings of styrene-maleic acid
anhydride copolymer, which was chosen as a polymer component (Schemes 2 and 3). In
this way, conjugates SMAC-EDA-Fen (5a) and SMAC-EDA-Gem (5b) were prepared
(Scheme 2). The reactions were performed in dry DMF, at 50 C, during 7 h. Unreacted
anhydride rings were hydrolyzed by hydrochloric acid.
More hydrophilic conjugates bearing free hydroxyethyl groups, SHM-EDA-Fen (6a)
and SHM-EDA-Gem (6b), were prepared by partial aminolysis of SMA with aminoami-
des 3a or 3b, followed by aminolysis of the remaining anhydride units with ethanola-
mine (Scheme 3). Reactions of SMA with compounds 3 were performed in dry DMF, at
50 C. The following reactions with ethanolamine proceeded at the same temperature, in
excess of the amine in order to prevent cross-linking.
Crude conjugates 5 and 6 were purified by precipitation: their DMF solutions were
poured into hydrochloric acid (w = 1%), the precipitated products were filtered off and
washed with water. The absence of nonconjugated drug was confirmed by TLC using
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cyclohexane/ethyl acetate/methanol (1:3:1), butanol/water/acetic acid (8:1:1) and cyc-
lohexane/ethyl acetate (1:1) solvent systems in which the polymer remained at the start
and drugs, benzotriazolides 2a,b or aminoamides 3a,b, moved with the mobile phase. IR
spectroscopy of conjugates 5a,b and 6a,b showed the absence of cyclic anhydride carbo-
nyl absorption at 1789 and 1855 cm–1 and the presence of strong carboxylic acid carbo-
nyl absorption between 1724 and 1734 cm–1. In this way, absence of unreacted anhydride
rings was confirmed. IR spectra of the conjugates showed also strong amide carbonyl
absorptions at ca 1650 (amide I) and 1540 (amide II), as well as N-H bond absorption at
3330 cm–1 (Fig. 1). In addition, conjugates 6a and 6b absorbed UV-light in the same ab-
sorption ranges as fenoprofen and gemfibrozil, whereas SMA showed no absorption at
these wavelengths. These IR and UV data could be considered as an additional proof
that drugs were covalently bound to the polymer in the prepared conjugates.
Drug loadings in conjugates 5a and 5b were calculated from the nitrogen content
and were found to be 46.9 and 41.3%, respectively. The amount of drug in conjugates 6a
and 6b was estimated by UV-spectroscopy using the molar absorption coefficient of fe-
noprofen in H2O (	272 = 1748 dm3 mol–1 cm–1) and gemfibrozil in 96% EtOH (	276 = 1866
dm3 mol–1 cm–1). Drug loadings of fenoprofen and gemfibrozil in conjugates 6a and 6b
were 29.6 and 17.0%, respectively.
The prepared polymer-drug conjugates differed in solubility. Conjugates 5a,b were
poorly soluble in water, even in the presence of a base, while SHM derivatives were so-
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luble in aqueous basic media and methanol. Better hydrosolubility of conjugates 6a and
6b was assured by less extensive drug loading and the presence of free hydroxyl groups.
CONCLUSIONS
Several polymer-drug conjugates of fenoprofen and gemfibrozil were synthesized
as potential macromolecular produgs: SMAC-EDA-Fen (5a), SMAC-EDA-Gem (5b), SHM-
-EDA-Fen (6a) and SHM-EDA-Gem (6b). Preliminary results showed that the prepared
polymer-drug conjugates underwent hydrolysis and released the bound fenoprofen and
gemfibrozil. However, detailed kinetic studies of chemical and potential enzyme hydro-
lysis still remain to be done.
Acronyms, abbreviations, symbols.  Bt  N-1-benzotriazolyl; BtH  benzotriazole; DMF
 N,N-dimethylformamide; EDA  ethylenediamine; Fen  fenoprofen residue without
carboxylic group; Gem  gemfibrozil residue without carboxylic group; NSAID  non-
-steroidal anti-inflammatory drug; SHM-EDA-Fen  (styrene-2-hydroxyethyl maleami-
de)-(styrene-maleic acid) copolymer-ethylenediamine-fenoprofen conjugate; SHM-EDA-
-Gem  (styrene-2-hydroxyethyl maleamide)-(styrene-maleic acid) copolymer-ethyle-
nediamine-gemfibrozil conjugate; SMA  styrene-maleic acid anhydride copolymer;
SMAC-EDA-Fen  (styrene-maleic acid copolymer)-ethylenediamine-fenoprofen conju-
gate; SMAC-EDA-Gem  (styrene-maleic acid copolymer)-ethylenediamine-gemfibrozil
conjugate; TEA  triethylamine.
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Fig. 1. Comparison of IR spectra of:
a) SMA (4), b) SMAC-EDA-Fen (5a)
and c) SHM-EDA-Fen (6a).
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S A @ E T A K
Sinteza konjugata fenoprofena i gemfibrozila s kopolimerom stirena
i maleinske kiseline
MARIJANA ZOVKO, MONIKA BARBARI], BRANKA ZORC, ANITA HAFNER i JELENA FILIPOVI]-GR^I]
U radu je opisana sinteza polimer-lijek konjugata polaze}i od kopolimera stirena i
anhidrida maleinske kiseline (SMA) i fenoprofena, odnosno gemfibrozila, ljekovitih tvari s
kratkim vremenom zadr`avanja u plazmi. Fenoprofen i gemfibrozil su prvo prevedeni u
2-aminoetilamide, koji su zbog slobodne amino skupine mogli reagirati s anhidridnim
prstenovima u SMA. Modifikacijom tipa i vrste supstitucije pripravljeni su lipofilni i hi-
drofilni konjugati. Udio vezanog lijeka u konjugatima bio je izme|u 17 and 47%.
Klju~ne rije~i: fenoprofen, gemfibrozil, polimer-lijek konjugati, makromolekularni prolijekovi, kopo-
limer stirena i anhidrida maleinske kiseline
Farmaceutsko-biokemijski fakultet, Zagreb
176
M. Zovko et al.: Synthesis of fenoprofen and gemfibrozil styrene-maleic acid copolymer conjugates, Acta Pharm. 55 (2005) 169–176.
